background subanalysi random clinic trial india pepsi survive benefit interleukin il blocked patient feature macrophages activationlik syndrome mal studi aim investing frequency develop biomass diagnosis prognosis method infect system inflammatory response assign one test cohort n valid diagnose score post either hemophagocyt score ndor hepatobiliari defunct dissemin intravascular coal list regrets analysis use est predict value day mortal cohort ferritin scd interferon gamma inγ tumor necrosis factor alpha tnα measure blood first h measure repeat result respect indeed risk level ngel accompany day level assoc increase infγ decrease infα ratio india predomin proinflammatori phenomenon le decrease density favor outcome high also valid swedish concur lifethreaten entity provide early may allow specify treatment 